| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/30/1998 | CA2268752A1 Plasmids encoding immunogenic proteins and intracellular as follows |
| 04/30/1998 | CA2268751A1 Fringe proteins and notch signalling |
| 04/30/1998 | CA2268746A1 Placental-derived prostate growth factors |
| 04/30/1998 | CA2268742A1 Multi-functional chimeric hematopoietic receptor agonists |
| 04/30/1998 | CA2268720A1 Induction of rev and tat specific cytotoxic t-cells for prevention and treatment of human immunodeficiency virus (hiv) infection |
| 04/30/1998 | CA2268276A1 Gene expression and delivery systems and uses |
| 04/30/1998 | CA2240843A1 Rotavirus antigens, vaccines and diagnostic drugs for infection with rotavirus, and processes for producing the same |
| 04/29/1998 | EP0838525A2 Streptococcus pneumoniae polypeptide greA |
| 04/29/1998 | EP0838523A2 RsbW-1 derived from Staphylococcus |
| 04/29/1998 | EP0838522A2 Coccidiosis poultry vaccine |
| 04/29/1998 | EP0838222A1 Vaccine compositions comprising inactivated immunogens and live chicken anaemia virus (CAV) |
| 04/29/1998 | EP0837939A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 04/29/1998 | EP0837936A1 New immunoregulatory protein lst-1 |
| 04/29/1998 | EP0837934A1 Human vascular endothelial growth factor 2 |
| 04/29/1998 | EP0837932A1 Macrophage activating factors derived from cloned vitamin d binding protein |
| 04/29/1998 | EP0837929A2 Marek's disease virus genes and their use in vaccines for protection against marek's disease |
| 04/29/1998 | EP0837928A1 Recombinant poxvirus - cytomegalovirus compositions and uses |
| 04/29/1998 | EP0837927A1 Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions |
| 04/29/1998 | EP0837926A2 Method for in vitro proliferation of dentritic cells, composition containing the cells entrapped in a three-dimensional matrix and use for immunization |
| 04/29/1998 | EP0837699A1 Immunovectors for the intracellular and intranuclear transport |
| 04/29/1998 | EP0837697A1 Anti-neutrophil cytoplasmic antibody material associated with ulcerative colitis and related methods and kits |
| 04/29/1998 | EP0837696A1 Improved delivery of diagnostic and therapeutic agents to a target site |
| 04/29/1998 | EP0837695A1 Actinomyces pyogenes and actinomyces pyogenes/fusobacterium necrophorum vaccines for immunizing cattle and sheep |
| 04/29/1998 | EP0837694A1 Leptospira membrane proteins |
| 04/29/1998 | EP0837693A1 Method of treating rheumatoid arthritis with low dose type ii collagen |
| 04/29/1998 | EP0837692A1 Clostridium difficile toxins as mucosal adjuvants |
| 04/29/1998 | EP0837691A1 Vaccination with peptide of mhc class ii molecules for treatment of autoimmune disease |
| 04/29/1998 | EP0837687A1 Hapten modified tumor cell extract and methods of treating or screening for cancer |
| 04/29/1998 | EP0837683A1 Preparation and use of sulfated oligosaccharides |
| 04/29/1998 | EP0837673A2 Polymeric lamellar substrate particles for drug delivery |
| 04/29/1998 | EP0837672A1 Preparations and methods for the treatment of t cell mediated diseases |
| 04/29/1998 | EP0722340B1 Immunological tolerance-inducing agent |
| 04/29/1998 | EP0537191B1 Treatment of organ transplantation rejection |
| 04/29/1998 | EP0465529B1 Expression of exogenous polynucleotide sequences in a vertebrate |
| 04/29/1998 | CN1180377A Human embryonic lung fibroblast diploid cell strain suitable for production of virus and process for production of varicella zoster virus using same |
| 04/29/1998 | CN1180374A Method of preparing undifferentiated cell |
| 04/29/1998 | CA2214866A1 Novel spo-rel |
| 04/28/1998 | US5744593 Parasitic helminth larval thiol specific antioxidant proteins and nucleic acid molecules |
| 04/28/1998 | US5744353 Cytolytic T cell lines which bind to complexes of tumor rejection antigens and HLA-B44 molecules |
| 04/28/1998 | US5744338 DNA encoding seryl tRNA synthetase from Staphylococcus aureus |
| 04/28/1998 | US5744316 Used to identify individuals diagnosed with conditions characterized by cellular abnormalities |
| 04/28/1998 | US5744144 Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| 04/28/1998 | US5744143 Viral vaccines |
| 04/28/1998 | US5744142 Self-assembling recombinant papillomavirus capsid proteins |
| 04/28/1998 | US5744141 Flavivirus recombinant poxvirus immunological composition |
| 04/28/1998 | US5744140 Recombinant poxvirus containing forein dna from encephalitis virus protein m or virus protein e, ns1, and ns2a |
| 04/28/1998 | US5744135 Method of raising an immune response with an anti-idiotypic antibody having correspondence with human hepatitis B surface antigen |
| 04/28/1998 | US5744134 Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| 04/28/1998 | US5744133 Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor |
| 04/23/1998 | WO1998016655A1 Human plasma hyaluronidase |
| 04/23/1998 | WO1998016649A1 Neuraminidase, coding sequences, compositions and methods |
| 04/23/1998 | WO1998016647A1 Hepatitis c virus epitope |
| 04/23/1998 | WO1998016646A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 04/23/1998 | WO1998016637A1 Fanconi gene 1 |
| 04/23/1998 | WO1998016558A1 METHOD FOR PRODUCING AN IgM PREPARATION FOR INTRAVENOUS ADMINISTRATION |
| 04/23/1998 | WO1998016553A1 Bordetella strain expressing the fha hybrid, liposomes and vaccines |
| 04/23/1998 | WO1998016552A1 Helicobacter pylori live vaccine |
| 04/23/1998 | WO1998016254A1 Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| 04/23/1998 | WO1998016250A1 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity |
| 04/23/1998 | WO1998016249A1 Methods and compositions for immunomodulation |
| 04/23/1998 | WO1998016248A1 Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12 |
| 04/23/1998 | WO1998016247A1 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 04/23/1998 | WO1998016246A1 Cytokine enhanced immunotherapy for brain tumors |
| 04/23/1998 | WO1998016238A2 Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
| 04/23/1998 | WO1998016205A2 Stable glassy state powder formulations |
| 04/23/1998 | WO1998009992A3 Htm4, methods of treatment and assays, agonists and antagonists |
| 04/23/1998 | WO1998009170A3 Methods and compositions for the detection of cervical cancer |
| 04/23/1998 | WO1998008548A3 Stable radioiodine conjugates and methods for their synthesis |
| 04/23/1998 | WO1998004711A3 Desaturase antigen of mycobacterium tuberculosis |
| 04/23/1998 | WO1998004702A3 Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use |
| 04/23/1998 | DE19643093A1 Verwendung von FasL oder mit FasL transfizierten CD4+/FasL-/TH1-Zellinien zur Behandlung von TH1/TH2-Krankheiten, Verfahren zur Herstellung von CD4+/FasL+/TH1-Zellinien und Stoffzusammensetzungen von FasL und einem oder mehren Cytokinen sowie dessen Verwendung zur Behandlung von TH1/TH2-Krankheiten Use of FasL or FasL transfected CD4 + / FasL / TH1 cell lines for the treatment of Th1 / Th2 diseases, processes for the production of CD4 + / FasL + / TH1-cell lines and compositions of FasL and to one or more cytokines, as well as its use for the treatment of Th1 / Th2 diseases |
| 04/23/1998 | CA2268340A1 Methods and compositions for immunomodulation |
| 04/23/1998 | CA2268033A1 Helicobacter pylori live vaccine |
| 04/23/1998 | CA2268008A1 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 04/23/1998 | CA2267977A1 Cytokine enhanced immunotherapy for brain tumors |
| 04/23/1998 | CA2267110A1 Fanconi gene i |
| 04/23/1998 | CA2266848A1 Method for producing an igm preparation for intravenous application |
| 04/22/1998 | EP0837138A2 Novel topoisomerase III |
| 04/22/1998 | EP0837137A2 Novel topoisomerase III |
| 04/22/1998 | EP0837136A2 Novel topoisomerase I |
| 04/22/1998 | EP0837133A2 DNA strand resolution proteins of the resolvase family |
| 04/22/1998 | EP0837130A2 M protein analogue from Streptococcus pneumoniae |
| 04/22/1998 | EP0836648A1 Recombinant mva virus, and the use thereof |
| 04/22/1998 | EP0836482A1 Subunit vaccine against flavivirus infection |
| 04/22/1998 | EP0836481A1 Parasitic helminth venom allergen antigen 5-like genes and proteins |
| 04/22/1998 | EP0836480A1 Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof |
| 04/22/1998 | EP0836380A1 Fgf9 as a specific ligand for fgfr3 |
| 04/22/1998 | EP0536275B1 Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
| 04/22/1998 | CN1179780A Peptides with growth promotion properties |
| 04/21/1998 | US5741893 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| 04/21/1998 | US5741715 Quinidine immunoassay and reagents |
| 04/21/1998 | US5741698 Isolated nucleic acid, vector, host cell |
| 04/21/1998 | US5741696 Recombinant equine herpesviruses |
| 04/21/1998 | US5741680 Buffer composition base and method of formulation for oral vaccine delivery |
| 04/21/1998 | US5741673 Nucleic acid encoding a novel homeobox factor which stimulates insulin expression in pancreatic islet cells |
| 04/21/1998 | US5741656 Epstein-Barr virus sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests |
| 04/21/1998 | US5741642 Assay for detecting the expression of a gene encoding human keratinocyte growth factor (KGF) |
| 04/21/1998 | US5741495 Glucan drug delivery system and adjuvant |
| 04/21/1998 | US5741494 Immunopotentiative and infection-protective agent containing bacillus and egg white |
| 04/21/1998 | US5741493 Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive |